Previously, we reporteda novel multitarget 2-(1H-indol-3-yl)ethan-1-aminecore which combined MAO-B selective inhibitionand NRF2 induction activities that demonstrated neuroprotective capacityin in vitro and ex vivo PD models. This evidence concerns the gene NFE2L2 and Parkinson disease.